BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stake Raised by Janus Henderson Group PLC

Janus Henderson Group PLC raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,907,533 shares of the company's stock after acquiring an additional 89,521 shares during the period. Janus Henderson Group PLC owned approximately 2.60% of BridgeBio Pharma worth $134,672,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BBIO. Vanguard Group Inc. grew its position in BridgeBio Pharma by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company's stock worth $413,738,000 after buying an additional 879,059 shares during the period. Farallon Capital Management LLC increased its stake in BridgeBio Pharma by 140.1% in the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company's stock valued at $115,111,000 after purchasing an additional 2,448,000 shares in the last quarter. Capital Research Global Investors increased its position in shares of BridgeBio Pharma by 34.9% in the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company's stock valued at $96,774,000 after buying an additional 912,439 shares in the last quarter. Ensign Peak Advisors Inc increased its position in shares of BridgeBio Pharma by 4.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 1,975,249 shares of the company's stock valued at $54,201,000 after buying an additional 89,495 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of BridgeBio Pharma by 23.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 1,885,794 shares of the company's stock worth $51,746,000 after buying an additional 353,570 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Trading Up 0.3%

Shares of BridgeBio Pharma stock traded up $0.10 during trading hours on Friday, reaching $33.84. 2,618,238 shares of the company's stock were exchanged, compared to its average volume of 2,435,517. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $39.54. The company has a fifty day moving average of $34.40 and a 200-day moving average of $31.47. The firm has a market capitalization of $6.43 billion, a price-to-earnings ratio of -11.87 and a beta of 1.15.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to analysts' expectations of $57.14 million. The firm's quarterly revenue was down 44.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.20) earnings per share. On average, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on BBIO shares. Redburn Atlantic initiated coverage on shares of BridgeBio Pharma in a research note on Monday, March 31st. They issued a "buy" rating and a $50.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research report on Friday, February 21st. UBS Group lifted their price objective on BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research report on Wednesday, April 30th. HC Wainwright increased their target price on BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Finally, JPMorgan Chase & Co. boosted their price target on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $57.09.

Insider Buying and Selling

In related news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total value of $197,760,000.00. Following the completion of the sale, the insider now directly owns 19,260,971 shares of the company's stock, valued at $634,841,604.16. The trade was a 23.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Maricel Apuli sold 1,026 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $38.51, for a total value of $39,511.26. Following the completion of the sale, the chief accounting officer now directly owns 147,639 shares in the company, valued at approximately $5,685,577.89. This trade represents a 0.69% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,410,217 shares of company stock valued at $417,634,332. 18.20% of the stock is currently owned by company insiders.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.